Navigation Links
Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
Date:3/22/2013

HAYWARD, Calif., March 22, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced its abstract entitled "Blisibimod, an Emerging Subcutaneous Biologic Therapy for Patients with Active, Moderate-to-Severe Systemic Lupus Erythematosus," has been selected as an oral presentation and will be presented at the 10th International Congress on Systemic Lupus Erythematosus by Dr. Morton Scheinberg , a rheumatologist at the Hospital Abreu Sodre Pesquisa Clinica in Sao Paulo, Brazil, on April 20, 2013.

Additionally, a poster entitled "Clinical Experience in Latin America With Blisibimod Amongst Subjects with Active, Moderate-to-Severe Systemic Lupus Erythematosus: Data From The Phase 2b PEARL-SC Study," will be presented by Dr. Scheinberg as part of the conferences Guided Poster Tours on April 19, 2013.

The poster will be available on www.anthera.com.

About Blisibimod and PEARL-SC

BAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, vasculitis, IgA nephropathy, immune thrombocytopenic purpura and others. Multiple clinical studies with other BAFF antagonists recently have reported on BAFF inhibitors potential positive role in treating lupus and rheumatoid arthritis. Anthera is advancing its development of blisibimod, a selective inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications.  The PEARL-SC Phase 2 study was designed as a ran
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
2. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
3. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
5. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
7. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
8. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
9. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
10. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
11. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... YORK , April 1, 2015   AMC ... solutions, will showcase advances in monitored care that are ... upcoming HIMSS 2015 Conference. The conference will ... , from April 12 through 16. In addition ... their respective booths, AMC Health will share innovations that ...
(Date:4/1/2015)...  Daiichi Sankyo, Inc., the US subsidiary of Daiichi ... with its US-based sister company, Asubio Pharmaceuticals, Inc.  As ... into the Daiichi Sankyo global development organization, led by ... Asubio Pharmaceuticals, parent company, Asubio Pharma Co., Ltd, which ... continue to operate as a wholly owned subsidiary of ...
(Date:4/1/2015)... Columbia and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), ... Erich Mohr , Ph.D., R.Psych., to its Board ... Mohr has close to two decades of biotechnology experience ... chief executive officer and board member, including serving as ...
Breaking Medicine Technology:AMC Health Demonstrates Advances in Monitored Care at HIMSS 2015 2AMC Health Demonstrates Advances in Monitored Care at HIMSS 2015 3AMC Health Demonstrates Advances in Monitored Care at HIMSS 2015 4Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge 2DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors 2DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors 3DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors 4
... March 6, 2012   Sunpeaks Ventures, Inc. ... Ventures") is pleased to provide this corporate update ... Ventures, through the recent acquisition of its wholly ... the specialty drug distribution sector.  The U.S. pharmaceutical ...
... 6, 2012  Marshall Edwards, Inc. (Nasdaq: MSHL ... of novel therapeutics targeting cancer metabolism, announced today that ... to the U.S. Food and Drug Administration (FDA) to ... Company,s lead mitochondrial inhibitor. "I am ...
Cached Medicine Technology:Sunpeaks Ventures Enters $45 Billion Specialty Drug Distribution Sector 2Sunpeaks Ventures Enters $45 Billion Specialty Drug Distribution Sector 3Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344 2Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344 3
(Date:4/1/2015)... Michigan (PRWEB) April 01, 2015 Parents ... Best Drug Rehabilitation’s blog, where the latest post discusses ... last month’s observation of Teen Dating Violence Awareness Month, ... on this growing problem to help parents identify if ... romantic interest that might involve drugs or alcohol. , ...
(Date:4/1/2015)... CHICAGO (PRWEB) April 01, 2015 Like ... too is the scientific understanding of the potential causes ... Month by the National Rosacea Society (NRS) to educate ... but treatable facial disorder now estimated to affect more ... long supported medical research on rosacea through its patient-funded ...
(Date:4/1/2015)... Dr. Rod J. Rohrich , ... the Department of Plastic Surgery at UT Southwestern Medical ... of blindness resulting from the use of facial ... their study, along with ideas for treatment and prevention ... began to see increasing reports of blindness as a ...
(Date:4/1/2015)... Dallas, Texas (PRWEB) April 01, 2015 ... Global Atorvastatin Calcium Industry is a professional and ... global Atorvastatin Calcium Market with a ... included in atorvastatin calcium market research are Pfizer, ... Laboratories Ltd, Sinochem Pharmaceuticals India Private Limited, Cadila ...
(Date:4/1/2015)... April 01, 2015 It is the meat ... breakfast but now found wrapped around other foods, infused into ... been called meat candy, the gateway meat for vegetarians and ... icon, the North American Meat Institute (NAMI) has developed a ... video tour of a bacon processing plant and ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Issues Toolkit for Teen Violence Related to Substance Abuse 2Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 2Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 3Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 4Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 5Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 2Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 3Health News:Atorvastatin Calcium Industry International & China Market Analysis 2015-2020 2Health News:Atorvastatin Calcium Industry International & China Market Analysis 2015-2020 3Health News:New Ultimate Guide to Bacon Video Provides Inside Look at How Bacon is Made 2
... ever study into the administration of blood thinning drugs, ... are at least as safe and reliable as those ... the value of these anticoagulant drugs in a wide ... or atrial fibrillation, has led to a rapid rise ...
... Affirms Industry Dominance, DALLAS, June 18 ... the leader in hosted services for email ... processed a record 20,million prescription transactions through ... accredited center. Over 3,200 active,prescribers across eight ...
... DATATRAK International,Inc. (Nasdaq: DATA ), a ... for the clinical trials industry, today announced that,it ... The Nasdaq Stock Market,("Nasdaq"), notifying the Company that ... 10, 2008, the bid price of the Company,s ...
... Insurance Convention Expected to Draw ... Protestors to San Francisco,Delgadillo to Discuss Legal Efforts to Crack Down ... and Unfair Business Acts and Practices" of Insurers, SAN ... of,protest against health insurance corporations, Los Angeles City Attorney,Rocky Delgadillo will ...
... leader of the team that made the discovery, Professor ... early diagnosis and treatment presents medical practitioners with the ... the discovery is at an experimental stage, this work ... disease," Professor Rowe says. , A 2004 Access Economics ...
... your marks, get set go to lane 1? ... the connection between loud sounds and reaction time are reporting ... at the upcoming Olympics. , Led by Dave Collins, ... researchers hypothesized that the loud starter,s pistol at the Olympic ...
Cached Medicine News:Health News:Computers as safe as medical experts in prescribing blood thinning drugs 2Health News:Zix Corporation Processes More Than 20 Million Electronic Prescriptions 2Health News:Zix Corporation Processes More Than 20 Million Electronic Prescriptions 3Health News:DATATRAK International, Inc. Receives Notice From Nasdaq 2Health News:DATATRAK International, Inc. Receives Notice From Nasdaq 3Health News:L.A. City Attorney Rocky Delgadillo, Patient Activists to Unveil New Television Ad Targeting Health Insurers 2Health News:L.A. City Attorney Rocky Delgadillo, Patient Activists to Unveil New Television Ad Targeting Health Insurers 3Health News:Advance towards early Alzheimer's diagnosis 2Health News:Sprinters closest to starter pistol have advantage over those farther away, says study 2
... Proven tension-free sling technology ... porcine acellular collagen matrix sling, ... tissue-to-tissue contact between sling and ... urethral or vaginal abrasion or ...
... Delivers the advanced performance ... exceptional strength, versatility, and durability ... implant that augments the effectiveness ... pelvic floor reconstruction. Comprised of ...
... system is a state-of-the-art, comprehensive cardiac ... programs, modalities, and parameters are highly ... multiple applications including cardiac and pulmonary ... clinics. Its open architecture delivers flexibility ...
NephroMax High Pressure Nephrostomy Balloon Catheter allows one-step, atraumatic dilatation of the nephrostomy tract....
Medicine Products: